Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine.
Authors:
- Samit R JoshiSJSamit R Joshi
- Albert C ShawASAlbert C Shaw
- Vincent J QuagliarelloVQVincent J Quagliarello
Open Access
- 1 December 2009
- journal article
- review article
- Vol. 82 (4) , 143-51
Abstract
Seasonal and pandemic strains of influenza have widespread implications for the global economy and global health. This has been highlighted recently as the epidemiologic characteristics for hospitalization and mortality for pandemic influenza H1N1 2009 are now emerging. While treatment with neuraminidase inhibitors are effective for seasonal and pandemic influenza, prevention of morbidity and mortality through effective vaccines requires a rigorous process of research and development. Vulnerable populations such as older adults (i.e., > age 65 years) suffer the greatest impact from seasonal influenza yet do not have a consistent seroprotective response to seasonal influenza vaccines due to a combination of factors. This short narrative review will highlight the emerging epidemiologic characteristics of pandemic H1N1 2009 and focus on immunosenescence, innate immune system responses to influenza virus infection and vaccination, and influenza vaccine responsiveness as it relates to seasonal and H1N1 pandemic influenza vaccines.Keywords
This publication has 55 references indexed in Scilit:
- Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009.2009
- Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and MiceScience, 2009
- Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in HumansScience, 2009
- Human innate immunosenescence: causes and consequences for immunity in old ageTrends in Immunology, 2009
- Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.2009
- DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trialVaccine, 2009
- The Intracellular Sensor NLRP3 Mediates Key Innate and Healing Responses to Influenza A Virus via the Regulation of Caspase-1Immunity, 2009
- Molecular and cellular signatures of human vaccine adjuvantsProceedings of the National Academy of Sciences, 2008
- The Pathology of Influenza Virus InfectionsAnnual Review of Pathology: Mechanisms of Disease, 2008
- Efficacy and effectiveness of influenza vaccines in elderly people: a systematic reviewThe Lancet, 2005